{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:38:22Z","timestamp":1777347502164,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Astellas Pharma, Inc. and Pfizer Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00465-3","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:32:18Z","timestamp":1773970338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone"],"prefix":"10.1186","volume":"12","author":[{"given":"Alan H.","family":"Bryce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nimke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiujun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Rozario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinal","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maelys","family":"Touya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"4","key":"465_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41391-024-00816-0","volume":"27","author":"DJ George","year":"2024","unstructured":"George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, et al. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024;27(4):756\u201364.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"465_CR2","doi-asserted-by":"publisher","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","volume":"4","author":"AO Elmehrath","year":"2021","unstructured":"Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, et al. Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw Open. 2021;4(8):e2119568.","journal-title":"JAMA Netw Open"},{"key":"465_CR3","doi-asserted-by":"publisher","first-page":"555475","DOI":"10.3389\/fphar.2020.555475","volume":"11","author":"M Wilk","year":"2020","unstructured":"Wilk M, Wasko-Grabowska A, Szmit S. Cardiovascular complications of prostate cancer treatment. Front Pharmacol. 2020;11:555475.","journal-title":"Front Pharmacol"},{"key":"465_CR4","unstructured":"Astellas Pharma US, Inc. Xtandi [prescribing information]; 2023."},{"key":"465_CR5","unstructured":"Janssen Pharmaceutical Companies. Zytiga [prescribing information]. 2021."},{"key":"465_CR6","doi-asserted-by":"publisher","first-page":"100887","DOI":"10.1016\/j.eclinm.2021.100887","volume":"36","author":"EB Cone","year":"2021","unstructured":"Cone EB, Reese S, Marchese M, Nabi J, McKay RR, Kilbridge KL, et al. Cardiovascular toxicities associated with abiraterone compared to enzalutamide-a pharmacovigilance study. EClinicalMedicine. 2021;36:100887.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"465_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clgc.2021.08.009","volume":"20","author":"J Hu","year":"2022","unstructured":"Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer. 2022;20(1):17\u201324.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"465_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","volume":"77","author":"G Lu-Yao","year":"2020","unstructured":"Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol. 2020;77(2):158\u201366.","journal-title":"Eur Urol"},{"issue":"2","key":"465_CR9","doi-asserted-by":"publisher","first-page":"102148","DOI":"10.1016\/j.jgo.2024.102148","volume":"16","author":"CE Gaber","year":"2025","unstructured":"Gaber CE, Okpara E, Abdelaziz AI, Sarker J, Hanson KA, Hassan L, et al. Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2025;16(2):102148.","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"465_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/ijc.34348","volume":"152","author":"HK Chen","year":"2023","unstructured":"Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, et al. Long-term use and risk of major adverse cardiac events: comparing enzalutamide and abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Int J Cancer. 2023;152(6):1191\u2013201.","journal-title":"Int J Cancer"},{"issue":"4","key":"465_CR11","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s12325-025-03132-8","volume":"42","author":"AS Merseburger","year":"2025","unstructured":"Merseburger AS, Dornstauder E, Ohlmann CH, Aprikian A, Junker S, Hahn P, et al. Cardiovascular risks and survival with abiraterone vs enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer in germany: Avenger study. Adv Ther. 2025;42(4):1919\u201334.","journal-title":"Adv Ther"},{"issue":"4","key":"465_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","volume":"26","author":"MW Schoen","year":"2023","unstructured":"Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA, et al. Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis. 2023;26(4):743\u201350.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"465_CR13","unstructured":"Medicare monthly enrollment. Data.CMS.gov. 2024. Available from: https:\/\/data.cms.gov\/summary-statistics-on-beneficiary-enrollment\/medicare-and-medicaid-reports\/medicare-monthly-enrollment. Cited March 25, 2025."},{"key":"465_CR14","unstructured":"Centers for Medicare & Medicade Services. Parts of Medicare. 2025. Available from: https:\/\/www.medicare.gov\/basics\/get-started-with-medicare\/medicare-basics\/parts-of-medicare."},{"issue":"4","key":"465_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41391-023-00757-0","volume":"27","author":"YHA Lee","year":"2024","unstructured":"Lee YHA, Hui JMH, Leung CH, Tsang CTW, Hui K, Tang P, et al. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: A retrospective cohort study. Prostate Cancer Prostatic Dis. 2024;27(4):776\u201382.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"465_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.120.047065","volume":"143","author":"SAE Peters","year":"2021","unstructured":"Peters SAE, Colantonio LD, Dai Y, Zhao H, Bittner V, Farkouh ME, et al. Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017. Circulation. 2021;143(7):650\u201360.","journal-title":"Circulation"},{"issue":"2","key":"465_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41391-024-00889-x","volume":"28","author":"JSK Chan","year":"2024","unstructured":"Chan JSK, Lee YHA, Leung CH, Leung DKW, Dee EC, Ng K, et al. Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study. Prostate Cancer Prostatic Dis. 2024;28(2):516\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"465_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40264-019-00867-6","volume":"43","author":"NM Schultz","year":"2020","unstructured":"Schultz NM, Penson DF, Wilson S, Song Y, Yang H, Ramaswamy K, et al. Adverse events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis. Drug Saf. 2020;43(1):23\u201333.","journal-title":"Drug Saf"},{"issue":"22","key":"465_CR19","doi-asserted-by":"publisher","first-page":"6984","DOI":"10.3390\/jcm12226984","volume":"12","author":"S Swamy","year":"2023","unstructured":"Swamy S, Noor SM, Mathew RO. Cardiovascular disease in diabetes and chronic kidney disease. J Clin Med. 2023;12(22):6984.","journal-title":"J Clin Med"},{"key":"465_CR20","doi-asserted-by":"publisher","first-page":"8295054","DOI":"10.1155\/2019\/8295054","volume":"2019","author":"R Bauersachs","year":"2019","unstructured":"Bauersachs R, Zeymer U, Bri\u00e8re JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019;2019:8295054.","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"465_CR21","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41391-021-00318-3","volume":"24","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, et al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021;24(4):1032\u201340.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6_suppl","key":"465_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2018.36.6_suppl.232","volume":"36","author":"V Kassabian","year":"2018","unstructured":"Kassabian V, Flanders S, Wilson S, Brown BA, Song Y, Yang H, et al. Health care resource utilization and costs in metastatic castration-resistant prostate cancer patients treated with enzalutamide or abiraterone acetate. J Clin Oncol. 2018;36(6_suppl):232.","journal-title":"J Clin Oncol"},{"issue":"10","key":"465_CR23","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s12325-018-0774-1","volume":"35","author":"NM Schultz","year":"2018","unstructured":"Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, et al. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naive patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis. Adv Ther. 2018;35(10):1639\u201355.","journal-title":"Adv Ther"},{"issue":"4","key":"465_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00465-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00465-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00465-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T02:55:29Z","timestamp":1777344929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00465-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00465-3","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AHB has received honoraria from Pfizer Inc., Janssen Pharmaceuticals, and Novartis. MT, DN, CY, QS, NR, and PK are employees of Astellas Pharma Inc. JI is an employee of Pfizer Inc. and holds stocks or other ownership interest in Pfizer Inc. IV is an employee of ADVI Health and holds stocks or other ownership interest in ADVI Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}